Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | EVI1 alteration in AML: mechanisms, disease risk & potential targeting

Ruud Delwel • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Transcription factor alterations in acute myeloid leukemia (AML) could be a key therapeutic target, as discussed here by Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands. Dr Delwel discusses his group’s research into EVI1 and the mechanisms of its alteration in AML. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Ruud Delwel

2:15
Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
Ruud Delwel • 15 Mar 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals